Zacks Investment ResearchThu, 18 Jun 2026 15:00:17 GMTCorcept Resubmits NDA for Relacorilant in Cushing's SyndromeCORT-0.08%
Zacks Investment ResearchMon, 08 Jun 2026 17:06:11 GMTCORT Stock Rises 42% in a Month: Here's What You Should KnowCORT-0.08%
Zacks Investment ResearchThu, 28 May 2026 15:16:15 GMTCORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock UpCORT-0.08%
Zacks Investment ResearchTue, 19 May 2026 14:55:41 GMTWall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to TradeCORT-0.08%
Zacks Investment ResearchFri, 15 May 2026 16:51:07 GMTWill Korlym Continue to Aid CORT's Growth in 2026 After a Strong Q1?CORT-0.08%
Seeking AlphaMon, 04 May 2026 18:53:10 GMTCorcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 AdvancementCORT-0.08%
Zacks Investment ResearchFri, 01 May 2026 16:15:34 GMTCORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook RaisedCORT-0.08%
BenzingaFri, 01 May 2026 14:52:10 GMTCorcept Therapeutics Pivotal Study Shows 87% Lower Death RiskCORT-0.08%
Seeking AlphaFri, 01 May 2026 09:31:34 GMTCorcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call TranscriptCORT-0.08%
Zacks Investment ResearchFri, 01 May 2026 01:45:17 GMTCorcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue EstimatesCORT-0.08%
